Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo.
Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecót T, Kladney RD, Shen C, Shim KS, Pham T, Karikomi MK, Mauntel MJ, Majumder S, Cuitino MC, Tang X, Srivastava A, Yu L, Wallace J, Mo X, Park M, Fernandez SA, Pilarski R, La Perle KM, Rosol TJ, Coppola V, Castrillon DH, Timmers C, Cohn DE, O'Malley DM, Backes F, Suarez AA, Goodfellow P, Chamberlin HM, Macrae ER, Shapiro CL, Ostrowski MC, Leone G. Caserta E, et al. Among authors: macrae er. Genes Dev. 2015 Aug 15;29(16):1707-20. doi: 10.1101/gad.262568.115. Genes Dev. 2015. PMID: 26302789 Free PMC article.
Treatment-related mortality with everolimus in cancer patients.
Wesolowski R, Abdel-Rasoul M, Lustberg M, Paskell M, Shapiro CL, Macrae ER. Wesolowski R, et al. Among authors: macrae er. Oncologist. 2014 Jun;19(6):661-8. doi: 10.1634/theoncologist.2013-0355. Epub 2014 May 2. Oncologist. 2014. PMID: 24794158 Free PMC article.
Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation.
Liu H, Dowdle JA, Khurshid S, Sullivan NJ, Bertos N, Rambani K, Mair M, Daniel P, Wheeler E, Tang X, Toth K, Lause M, Harrigan ME, Eiring K, Sullivan C, Sullivan MJ, Chang SW, Srivastava S, Conway JS, Kladney R, McElroy J, Bae S, Lu Y, Tofigh A, Saleh SMI, Fernandez SA, Parvin JD, Coppola V, Macrae ER, Majumder S, Shapiro CL, Yee LD, Ramaswamy B, Hallett M, Ostrowski MC, Park M, Chamberlin HM, Leone G. Liu H, et al. Among authors: macrae er. Dev Cell. 2017 May 22;41(4):392-407.e6. doi: 10.1016/j.devcel.2017.04.024. Dev Cell. 2017. PMID: 28535374 Free PMC article.
Metastatic breast cancer patient perceptions of somatic tumor genomic testing.
Adams EJ, Asad S, Reinbolt R, Collier KA, Abdel-Rasoul M, Gillespie S, Chen JL, Cherian MA, Noonan AM, Sardesai S, VanDeusen J, Wesolowski R, Williams N, Shapiro CL, Macrae ER, Pilarski R, Toland AE, Senter L, Ramaswamy B, Lee CN, Lustberg MB, Stover DG. Adams EJ, et al. Among authors: macrae er. BMC Cancer. 2020 May 6;20(1):389. doi: 10.1186/s12885-020-06905-2. BMC Cancer. 2020. PMID: 32375690 Free PMC article. Clinical Trial.
Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions.
Stover DG, Reinbolt RE, Adams EJ, Asad S, Tolliver K, Abdel-Rasoul M, Timmers CD, Gillespie S, Chen JL, Ali SM, Collier KA, Cherian MA, Noonan AM, Sardesai S, VanDeusen J, Wesolowski R, Williams N, Lee CN, Shapiro CL, Macrae ER, Ramaswamy B, Lustberg MB. Stover DG, et al. Among authors: macrae er. JCO Precis Oncol. 2019 Nov 18;3:PO.19.00090. doi: 10.1200/PO.19.00090. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32923860 Free PMC article.
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman RM, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd GT, Harris L, Isaacs C, Dees C, Perou CM, Johnson GL, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover DG, Ramaswamy B. Prasath V, et al. Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07551-z. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39644403
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Hicks M, et al. Among authors: macrae er. Oncologist. 2015 Apr;20(4):337-43. doi: 10.1634/theoncologist.2014-0334. Epub 2015 Mar 2. Oncologist. 2015. PMID: 25732265 Free PMC article.
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B. Wesolowski R, et al. Oncologist. 2020 Aug;25(8):e1158-e1169. doi: 10.1634/theoncologist.2020-0039. Epub 2020 Jun 17. Oncologist. 2020. PMID: 32452601 Free PMC article. Clinical Trial.
25 results